Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elin M Svensson

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TBElin M Svensson, Mats O Karlsson
Journal of Pharmacokinetics and Pharmacodynamics|March 14, 2014
Use of a linearization approximation facilitating stochastic model buildingElin M Svensson, Mats O Karlsson
British Journal of Clinical Pharmacology|December 17, 2019
Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosisLénaïg Tanneau, Mats O Karlsson, Elin M Svensson
Antimicrobial Agents and Chemotherapy|August 13, 2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfectionElin M Svensson, Kelly E Dooley, Mats O Karlsson
CPT: Pharmacometrics & Systems Pharmacology|October 9, 2021
Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosisLénaïg Tanneau, Elin M Svensson, Stefaan Rossenu, et al.
Clinical Pharmacokinetics|June 30, 2025
A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose SelectionYuanxi Zou, Jerry Nedelman, Mats O Karlsson, et al.
The Journal of Antimicrobial Chemotherapy|August 1, 2024
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TBYu-Jou Lin, Yuanxi Zou, Mats O Karlsson, et al.
The Journal of Antimicrobial Chemotherapy|December 24, 2014
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drugElin M Svensson, Stephen Murray, Mats O Karlsson, et al.
Breathe (Sheffield, England)|March 19, 2025
The importance of getting the dose right in the treatment of tuberculosisAndrii Dudnyk, Wandini Lutchmun, Raquel Duarte, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2026
An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With TuberculosisYu-Jou Lin, Frances Okibedi, Mats O Karlsson, et al.
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TBElin M Svensson, Mats O Karlsson
Journal of Pharmacokinetics and Pharmacodynamics|March 14, 2014
Use of a linearization approximation facilitating stochastic model buildingElin M Svensson, Mats O Karlsson
British Journal of Clinical Pharmacology|December 17, 2019
Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosisLénaïg Tanneau, Mats O Karlsson, Elin M Svensson
Antimicrobial Agents and Chemotherapy|August 13, 2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfectionElin M Svensson, Kelly E Dooley, Mats O Karlsson
CPT: Pharmacometrics & Systems Pharmacology|October 9, 2021
Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosisLénaïg Tanneau, Elin M Svensson, Stefaan Rossenu, et al.
Clinical Pharmacokinetics|June 30, 2025
A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose SelectionYuanxi Zou, Jerry Nedelman, Mats O Karlsson, et al.
The Journal of Antimicrobial Chemotherapy|August 1, 2024
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TBYu-Jou Lin, Yuanxi Zou, Mats O Karlsson, et al.
The Journal of Antimicrobial Chemotherapy|December 24, 2014
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drugElin M Svensson, Stephen Murray, Mats O Karlsson, et al.
Breathe (Sheffield, England)|March 19, 2025
The importance of getting the dose right in the treatment of tuberculosisAndrii Dudnyk, Wandini Lutchmun, Raquel Duarte, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 12, 2026
An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With TuberculosisYu-Jou Lin, Frances Okibedi, Mats O Karlsson, et al.
Pageof 11